Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. Why Do MMJ Patients Use Cannabis?

Access 98

Access Patients Chronic Pain Conditions 98

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. Although both studies will enroll 25 patients initially, the U.S. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 12, 2019

Ultimately, the cannabinoid system works by way of multiple molecules affecting multiple receptors at once – the entourage effect, and thus such singular approaches to treatment by way of the cannabinoid system are not effective. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Epilepsy Behav. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments as and when we judge that to be in the best interest of the patients.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. RECENT DEVELOPMENTS.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. CBG, however, also has some medicinal potential that CBD doesn’t, for instance as a treatment for hypertension and insulin resistance. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

DECEMBER 1, 2019

A young girl with a drug-resistant form of epilepsy is believed to be the first and only patient in Singapore who has been given approval to use cannabis-derived medication. The move follows approvals by lawmakers in the United States to use the medication to treat rare kinds of childhood epilepsy in that country.

Epilepsy 59

Epilepsy Cannabinoids Therapy Treatment 59

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Veriheal

DECEMBER 28, 2021

This is according to recent data from a report published by Market Research Future (MRT) – a pioneer in market analysis. The report authors noted that THC, on the other hand, is touted as a popular option for alleviating the negative effects of AIDS and cancer treatment. Amyotrophic lateral sclerosis (ALS). Alzheimer’s.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Cannabis Chronicles

JANUARY 2, 2019

drug regulators approved the first marijuana-based pharmaceutical to treat kids with a form of epilepsy, and billions of investment dollars poured into cannabis companies. It’s a non-psychoactive compound found in marijuana and hemp plants and used for treatment of certain medical problems. It’s not just the U.S.

Legalization 100

Legalization Research and Development Recreational Data 100

Cannabis Law Report

APRIL 4, 2019

Further there is a growing body of evidence that various forms of cannabis could help in the treatment of epilepsy and seizures, post-traumatic stress disorder (PTSD), glaucoma, dementia, Alzheimers, autism, fibromyalgia and a range of auto-immune diseases.

Cultivation 40

Cultivation Research and Development Chronic Pain Data 40

CannaTech

SEPTEMBER 23, 2019

This bottleneck has left patients and parents to pursue unregulated avenues to access treatment. Furthermore, pharmaceutical companies often fund and initiate randomised clinical trials to validate their drugs. While prioritizing clinical trials is an important step, denying the efficacy of cannabis is irresponsible and short-sighted.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Veriheal

MARCH 23, 2023

Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products. The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. physicians began over-prescribing opioids like oxycodone due to reassurance from pharmaceutical companies that they were not addictive—which patients quickly discovered to be untrue.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Veriheal

JULY 5, 2021

Titled “ The Effectiveness of Common Cannabis Products for Treatment of Nausea ”, the newly published study indicates that most medical cannabis patients who endure nausea prefer to load up on THC, as opposed to CBD. The self-reported data was logged between June 6, 2016, and July 8, 2019. billion in legal U.S.

THC 52

THC CBD Treatment Cannabinoids 52

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. For instance, as of June 2021, InMed Pharmaceuticals, Inc., List To Data Sources. Key Topics Covered: Chapter 1 Methodology and Scope.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

JUNE 1, 2021

Prior to UroGen, Mr. Barbera held various leadership roles at Dendreon Pharmaceuticals, Allergan, and Medimmune, among others. About Vicineum™ Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

WeedAdvisor

APRIL 8, 2019

The only actual confirmed benefit of CBD is its effect on Lennox Gastaut Syndrome and Dravet Syndrome – two severe types of epilepsy that do not typically respond to conventional treatment. This led to Epidiolex, the first FDA-approved pharmaceutical drug derived from CBD for the sole purpose of treating LGS and Dravet.

Food 40

Food CBD Research and Development Treatment 40

Cannabis Law Report

SEPTEMBER 19, 2019

Medicinal cannabis was technically legalised at the start of November 2018 following several high-profile cases about children with severe forms of epilepsy being unable to access potentially life-changing cannabis-based treatment. GW Pharmaceuticals ?and GW Pharmaceuticals. GW Pharmaceuticals?is policy, and?could

Pharmaceutical 40

Pharmaceutical Research and Development Medicine Oil 40

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Palliative care indications. Cancer pain.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 9, 2019

Although official uses (outside of treatment for childhood epilepsy) have not been officially approved by the FDA, early results from research has resulted in consumers flocking to the compound of their own accord and at their own risk. Natural remedies are very appealing to most pet owners. Anxiety and Inflammation Lead the Pack.

Pets 59

Pets CBD Research and Development Epilepsy 59